Online inquiry

IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13543MR)

This product GTTS-WQ13543MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MCAM gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_006500.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4162
UniProt ID P43121
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13543MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13458MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ4495MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ2228MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ2881MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ7102MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ6952MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5063MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ3260MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ART621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW